These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 7705563)

  • 1. [Chronic lesion of the interlobular bile ducts induced by fenofibrate].
    Lepicard A; Mallat A; Zafrani ES; Dhumeaux D
    Gastroenterol Clin Biol; 1994; 18(11):1033-5. PubMed ID: 7705563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronic active cirrhogenic hepatitis induced by fenofibrate].
    Chatrenet P; Regimbeau C; Ramain JP; Penot J; Bruandet P
    Gastroenterol Clin Biol; 1993; 17(8-9):612-3. PubMed ID: 8253329
    [No Abstract]   [Full Text] [Related]  

  • 3. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gynecomastia associated with fenofibrate.
    Gardette V; Vezzosi D; Maiza JC; Montastruc JL; Olivier P
    Ann Pharmacother; 2007 Mar; 41(3):508-10. PubMed ID: 17341535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Importance of liver puncture biopsy and endoscopic retrograde cholangiography in patients with chronic anicteric unexplained cholestasis. A retrospective study in 79 patients].
    Sapey T; Turlin B; Canva-Delcambre V; Mendler MH; Deugnier Y; Brissot P; Guyader D
    Gastroenterol Clin Biol; 1999 Feb; 23(2):178-85. PubMed ID: 10353011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
    Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
    Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional, biochemical, and morphological hepatobiliary effects in rats chronically exposed to a steroidal antiandrogen.
    Descotes G; Osman H; Gallas JF; Penacchio E; Moreau C
    Toxicol Appl Pharmacol; 1996 Mar; 137(1):23-33. PubMed ID: 8607138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Follow-up of benign recurrent intrahepatic cholestasis (Summerskill-Walshe-Tygstrup syndrome) over 46 years].
    Cissarek T; Schumacher B; Schwöbel H; Sarbia M; Neuhaus H
    Z Gastroenterol; 1998 May; 36(5):379-83. PubMed ID: 9654705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile secretory function after warm hepatic ischemia-reperfusion injury in the rat.
    Accatino L; Pizarro M; Solís N; Arrese M; Koenig CS
    Liver Transpl; 2003 Nov; 9(11):1199-210. PubMed ID: 14586882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlorpromazine-induced cholestatic liver disease with ductopenia.
    Chlumská A; Curík R; Boudová L; Mukensnabl P; Klvana P
    Cesk Patol; 2001 Jul; 37(3):118-22. PubMed ID: 11669021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J; Ye P
    Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
    Hottelart C; el Esper N; Achard JM; Pruna A; Fournier A
    Nephrologie; 1999; 20(1):41-4. PubMed ID: 10081035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.
    Jacquemin E; Hermans D; Myara A; Habes D; Debray D; Hadchouel M; Sokal EM; Bernard O
    Hepatology; 1997 Mar; 25(3):519-23. PubMed ID: 9049190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infantile cholestasis due to cytomegalovirus infection of the liver. A possible cause of paucity of interlobular bile ducts.
    Kage M; Kosai K; Kojiro M; Nakamura Y; Fukuda S
    Arch Pathol Lab Med; 1993 Sep; 117(9):942-4. PubMed ID: 8396386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide.
    Vuppalanchi R; Chalasani N; Saxena R
    Am J Surg Pathol; 2006 Dec; 30(12):1619-23. PubMed ID: 17122520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.
    Mallat A; Zafrani ES; Metreau JM; Dhumeaux D
    Dig Dis Sci; 1997 Jul; 42(7):1486-8. PubMed ID: 9246051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute cholestatic hepatitis induced by fenofibrate.
    Hajdu D; Aiglová K; Vinklerová I; Urbánek K
    J Clin Pharm Ther; 2009 Oct; 34(5):599-602. PubMed ID: 19744016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.
    Altraif I; Lilly L; Wanless IR; Heathcote J
    Am J Gastroenterol; 1994 Aug; 89(8):1230-4. PubMed ID: 8053440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.